Disclosure under Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regarding approval of Scheme of Amalgamation and Arrangement Intimation regarding receipt of Observation letters from the National Stock Exchange of India Limited and BSE Limited in relation to the proposed Scheme of Amalgamation and Arrangement between Dhanuka Laboratories Limited ('Transferor Company') and Orchid Pharma Limited ( 'Transferee Company' } and their respective shareholders and creditors ('Scheme') (As Per BSE Announcement Dated 30.03.2022) Update - Disclosure under Regulation 30 of SEBI LODR 2015. (As per BSE Announcement Dated on 23/9/2022) Announcement under Reg. 30 of SEBI LODR 2015 Further to our announcement dated September 23, 2022, the Company went ahead with filing an appeal against the order of National Company Law Tribunal (NCLT), Chennai Bench dated September 09, 2022, before the National Company Law Appellate Tribunal (NCLAT), Chennai Bench on December 05, 2022 to pray for setting aside of the said order of NCLT, Chennai and for directing NCLT, Chennai to give a fresh opportunity of being heard to the Company. However, it considers pragmatic to defer the proposed Scheme of Amalgamation and arrangement between Dhanuka Laboratories Limited (Amalgamating Company) and Orchid Pharma Limited (Amalgamated Company) and their respective shareholders and creditors ('Proposed Amalgamation'). Accordingly, the Company has withdrawn the appeal filed before NCLAT and the order of NCLAT dated January 05, 2023 evidences this. (As Per BSE Announcement dated on 09.01.2023)